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It is well known that the mutations in BRCA1 or BRCA2 gene can cause
the hereditary breast cancer. However, it is a tedious and expensive task to
identify the mutant genes that impact breast cancer due to the large number of
genes and very small number of samples. Researchers have hypothesized that the
genes expressed by these two types of tumors are also distinctive. The number of
expressed genes could also be very high compared with the actual number of genes
that has impact on the cases of breast cancer. Furthermore, the expressive energy
of the subset of genes in place of that of one individual gene at a time can be
considered to have a profound influence on the cases of breast cancer. Therefore,
the objective of this study is to propose a method to identify a small subset of
xvii
high-impact genes that are strongly related to breast cancer.
A combination of a non-parametric supervised and an unsupervised statistical
method is introduced to analyze the gene expressions and the distinctive genes
among the highly expressed genes are identified. The most important genes are fil-
tered using the area under the curve (AUC) measure. These filtered genes are then
used to build a hidden Markov model (HMM) to analyze their inter-relationship
and identify the best subset among them. In addition, Protein-Protein interac-
tion network is generated to analyze the pathways of the identified genes and their
link with BRCA1 or BRCA2. Transcription Factors are identified and Gene Set
Enrichment Analysis (GSEA) is calculated for the identified genes subset and the
results are compared with the results mentioned in other cancer literature.
The identified genes are not only statistically significant but also illustrate bi-
ological significance related to the disease. These genes are also common among
the genes that have been identified by other existing studies and gene path-
ways/ontology analysis. Moreover, the subset of genes extracted by our method
is more compact than those previously investigated. Therefore, most of the genes
identified by the hybrid method are known to be strongly related to breast cancer.
xviii
ملخص الرسالة
عمران الحق أبصار الحق  : الاسم الكامل
 و ال MMH طريقة جديدة لإختيار الأنماط الظاهرية ذات التأثير العالي عن طريق دمج ال  : عنوان الرسالة
 CUA
علوم حاسب آلي  :  التخص
 2102 كانون أول  : تاريخ الدرجة العلمية
سرطان الثدي الوراثي. تعتبر عملية  2ACRBو الجين  1ACRBمن المعلوم أن الطفرات التي تحصل على الجين 
تحديد و إكتشاف الجينات التي تأثرت بالطفرات عمليه صعبة و مكلفة بسبب عدد الجينات الكبير جدا، و العدد القليل 
النوعين من الأورام. عدد الجينات المتأثرة بالأورام قد  من العينات. يفترض العلماء إختلاف الجينات المتأثره بهذين
الناتجة من  يكون مرتفعا أيضا مقارنة بالعدد الفعلي للجينات التي تؤدي إلى سرطان الثدي. كما أن، الطاقة المؤثرة
دي. مجموعه جزئية من الجينات في مكان معين يمكن أن تؤثر بشكل أكبر من تأثير جين واحد في حالة سرطان الث
تهدف هذه الدراسة إلى تطور تقنيه لتحديد مجموعة جزئية واحدة من الجينات ذوات التأثير العالي المرتبطة بقوة 
بسرطان الثدي.
قمنا في هذه الدراسة بتطوير طرق إحصائية غير مراقبة و طرق إحصائية غير حدودية مراقبة لتحليل تعابير الجينات 
ات التأثير العالي. تم تصفية الجينات ذات الأهمية العالية بإستخدام مقياس المساحة و الجينات المميزة بين الجينات ذ
) من MMH). بعد ذلك تم إستخدام الجينات المصفاه في عملية بناء نموذج ماركوف المخفي (CUAتحت المنحنى (
م بناء شبكة تفاعل بين أجل تحليل علاقاتهم الداخلية و تحديد أفضل مجموعة جزئية بينهم. بالإضافة إلى ذلك، ت
قمنا بتحديد عوامل  .2ACRBو   1ACRBالبروتينات بهدف تحليل مسارات الجينات المختارة و إرتباطهم بالجينات
xix
 xx
 )AESG( sisylanA tnemhcirnE teS eneG)، بالإضافة إلى حساب srotcaF noitpircsnarTالنسخ (
الخاصة بالمجموعات الجزئية للجينات. ثم قمنا بالمقارنة النتائج مع النتائج الخاصة بأبحاث السرطان الأخرى.
لا ينحصر تأثير الجينات المحددة على الجانب الإحصائي فقط، ولكن تبين أنها تملك تأثيرات حيوية مرتبطة مرض. 
بالإضافة إلى ذلك تظهر هذه الجينات بين الجينات التي تم أكتشافها في الدراسات الأخرى و مسارات الجينات. تتميز 
ترحة في هذه الدراسة، بصغر حجمها مقارنة بنتائج الدراسات المجموعة الجزئية المستخرجة بإستخدام الطريقة المق
الأخرى. أخيرا، تبين أن معظم الجينات التي تم تحديدها معروفة بعلاقتها القوية بسرطان الثدي.
Chapter 1
Introduction
The research presented in this thesis develops and analyzes a hybrid computational
method to select important high-impact genes in a high dimensional dataset.
This research is based on area under the curve (AUC) and hidden Markov model
(HMM). A HMM is a statistical process used to model sequential processes in
which a future event depends on the current event. Examples that represent
sequential process are the sequence of letters in an alphabet and time series data
where the collection of observations on variables created sequentially in time [8].
This chapter is organized as follow. The preliminary information regarding
the genomic era, bioinformatics, cancer, breast cancer and why is it necessary to
better understand breast cancer is presented in Section 1.1. Section 1.2 presents
an overview of the gene selection and answer questions like why is it necessary,
what are the prominent approaches and what is still missing?. Section 1.3 presents
aim of this thesis. Finally, the organization of this thesis is described in Section
1.4.
1
1.1 Preliminaries
1.1.1 The genomic era
On 26th June 2000, geneticists announced to the world that they had successfully
deciphered the human genome. This discovery opened thousands of new doors for
scientific research, offering untold opportunities for better health, longer lives and
richer human understanding. This marked the beginning of the genomic era and
resulted in a massive explosion in the amount of biological information available
due to huge advances in the fields of molecular biology and genomics [9].
1.1.2 Bioinformatics
This massive explosion also resulted in the rediscovering of the bioinformatics field.
Bioinformatics is the application of computer technology to the management and
analysis of biological data [9]. The ultimate goal of bioinformatics is to uncover
the wealth of biological information hidden in the massive data and obtain a
clearer insight into the fundamental biology of organisms. This new knowledge
can have profound impact on fields as varied as human health, agriculture, the
environment, energy and biotechnology.
1.1.3 Cancer
Cancer is a condition in which abnormal cells divide without control and are able
to invade other tissues [10]. These cells can begin to grow and divide abnormally
and escape our bodys normal control processes. Cancer does not refer to a single
disease but many diseases. There are more than 100 different types of cancer [10],
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mostly named for the organ or the type of cell in which they initiate, for example
colon cancer, skin cancer and breast cancer.
1.1.4 Breast Cancer
Cancer that starts in the tissues of the breast is known as breast cancer [11].
There are two types of breast cancer; hereditary breast cancer that is associated
with inherited gene mutations, and non-hereditary (sporadic) breast cancer that
is associated with diagnosis without a prior history of cancer in the family. The
two most frequent cancer types worldwide are breast and ovarian cancer among
women [12]. Trailing lung cancer, breast cancer is the second most common type
of cancer in the world and is the fifth most common cause of death from cancer
[12].
1.1.5 What’s missing?
The above mentioned statistics highlight the importance of understanding breast
cancer in more detail. One way to better understand breast cancer is to investigate
the patients that have suffered from it. More specifically, in depth examination of
the gene microarrays of patients that suffered from breast cancer can result in new
information. The genes present in these gene microarrays can be studied at the
individual as well as the group level. The ultimate goal is to successfully determine
a list of genes whose product abundance can indicate important differences in cell
state, such as healthy or damaged, or also in identification of one particular type
of cancer or another. Moreover, among these informative genes, some may play a
role in the initiation, progression, or maintenance of the disease.
3
1.2 Gene selection
In the last decade, gene expression data have become an increasingly popular way
of exploring the genotypic influences underlying the poorly understood pheno-
types. For example, BRCA1 and BRCA2 are well known human genes wherein
the mutation of the genes can be linked to the hereditary breast cancer as well as
ovarian cancer [13; 14; 15; 16]. Mutations in BRCA gene are somehow heteroge-
neous, i.e., one normal and the other is mutated copy considering germ-line i.e.,
the line (sequence) of germ cells that have genetic material that may be passed
to a child. Interestingly, BRCA1 mutation carriers are more susceptible to having
breast cancer than that of BRCA2 (the risk is up to 80% [16; 17]). Moreover,
there is an increased risk of ovarian cancer to the carriers with BRCA1 mutations
[18]. However, the risk of BRCA2 mutations can approach to that of BRCA1 with
time [19]. Gene expression data analysis can be useful in identifying a gene subset
that influences the varying risk factor in between BRCA1 and BRCA2 mutations.
Approaches to extract information from gene expression data fall into several
major categories. The earliest and the most straightforward category consists
of looking for the individual genes whose expression difference between the two
mutations falls significantly close to one extreme, i.e. BRCA1 or BRCA2. These
methods search for genes whose uncharacteristically extreme behavior demon-
strates that they are related to the underlying phenotypic difference. Investigators
then take this list of exceptional genes and try to explain the link between their
differential expression and the different conditions they exhibit.
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While search for the significance of individual and distinctively expressed genes
has yielded many insights [1, 4, 20], it seems increasingly likely that relevant
biological deviations in many cases may be too subtle at a single gene to be
detectable by such a method [21]. To address this issue, increasing number of
methods take broader look into the gene expression and exploit the advantage of
the extensive information captured in the data.
1.3 Aim of this research
The aim of this research is to develop, implement, test a coherent and powerful
method for the selection of important and high-impact genes from a gene ex-
pression dataset, report the test results and compare them with existing studies.
A combination of a non-parametric supervised and an unsupervised statistical
method is introduced to analyze the gene expression dataset and the distinctive
genes among the highly expressed genes are identified.
The aim of this research is to develop a simple and easy to under-
stand hybrid method using a combination of AUC and HMM intended
to be a powerful model for selection of important high-impact genes
from a high dimensional gene expression dataset.
1.4 Organization of the thesis
The thesis is organized as follows. Chapter 2 contains the background of the
various techniques employed in this research. Chapter 3 discusses the existing
techniques for feature selection. Chapter 4 presents the summary of recent and
5
popular researches that has been done regarding feature selection in high dimen-
sional datasets. In Chapter 5, we discuss our proposed hybrid model in detail.
Chapter 6 comprises the results that have been achieved from existing techniques
discussed in Chapter 3. In Chapter 7, we describe the experimental setup, the
dataset used and results achieved from our proposed hybrid method. Chapter 8
discusses the impact of our work where we compare the results of our work with
the existing studies biologically and statistically. In the last chapter i.e., Chapter
9, we conclude this research and discuss the significance of our work.
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Chapter 2
Background
This thesis discuss the design and analysis of a hybrid feature selection method
which combines AUC and HMM. Therefore, a brief theory on these techniques
is presented in this chapter. Furthermore, a brief description of Baum-Welch
expectation maximization 22 algorithm is also discussed.
This chapter is organized as follows. Section 2.1 presents the preliminary
information that need to be understood before discerning ROC and AUC. The
receiver operating characteristic (ROC) curve is discussed in Section 2.2. Section
2.3 briefly describes the theory of area under the ROC curve (AUC). Section 2.4
outlines the HMM model. A brief theory of Baum-Welch expectation maximiza-
tion [22] algorithm is presented in Section 2.5.
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2.1 Preliminaries
2.1.1 Classification
In machine learning, classification is a type of supervised learning i.e. learning
where a training set of correctly-identified observations is available.
Formally, classification is the problem of identifying to which set of categories,
a new instance belongs based on a training set of data containing instances whose
class is known.
2.1.2 Binary Classification
In binary classification, only two classes are involved. Formally, each instance I is
mapped to one element of the set of positive and negative class labels i.e., {+,-}
or {p,n} [23].
2.1.3 Classification model
A classification model, also called classifier, maps instances to predicted classes
[23].
In order to distinguish between the actual class and the predicted class, differ-
ent labels can be used for the class predictions produced by a model like {Y,N}.
2.1.4 Binary Classification Outcomes
The four possible outcomes from a binary classifier and an instance are as follows.
true positive: If the instance is positive and it is correctly classified as positive
false negative: If the instance is positive and it is incorrectly classified as negative
true negative: If the instance is negative and it is correctly classified as negative
8
false positive: If the instance is negative and it is incorrectly classified as positive
True Class
Predicted 
Class
p n
Y
N
True
Positives
True
Negatives
False
Positives
False
Negatives
Column Totals: P N
fp rate =  FP  
                N 
tp rate =  TP 
                P
precision =      TP 
                   TP + FP
fp rate =  FP
               N
accuracy =  TP + TN
                      P + N
Figure 2.1: Confusion matrix and common performance metrics calculated from
it
Let us discuss an appropriate example from a real-world problem in order
to better understanding the above mentioned terms. Consider a diagnostic test
that tries to determine whether a person has a certain disease or not. A false
positive in this example would be when the person tests positive, but he does
not have the disease. Conversely, a false negative occurs when the person tests
negative, suggesting he is healthy, when he actually have the disease. The other
two simpler terms are true positive, test indicate the person having the disease,
and true negative the test indicate the person not having the disease.
A 2x2 confusion matrix, also called a contingency table, can be constructed
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representing the dispositions of the set of instances from a classifier and a set of
instances. Figure 2.1 shows a confusion matrix and equations of several common
metrics that can be calculated from it.
2.1.5 Markov Process
A Markov process is a stochastic process where the future event depends on the
immediate preceding event. Hence, a Markov process assumes that the probability
of the occurrence of the next event will solely depend on the occurrence of the
current event.
Figure 2.2: A sequence of letters: A, B and C
Let us understand this with a simple example of a sequence of letters shown in
Figure 2.2. In this sequence, the total number of changes, as the next step value
in the sequence, from A to A is 2, from A to B is 2, from A to C is 1; from B to
A is 2, from B to B is 1, from B to C is 1; from C to A is 1, from C to B is 1 and
from C to C is 1. The conditional probabilities for the given sequence are:
Pr(A|A) = 2/13; Pr(A|B) = 2/13; Pr(A|C) = 2/13
Pr(B|A) = 2/13; Pr(B|B) = 1/13; Pr(B|C) = 1/13
Pr(C|A) = 1/13; Pr(C|B) = 1/13; Pr(C|C) = 1/13
The sequence of letters shown in Figure 2.2 can also be illustrated using a
directed graph as shown in Figure 2.3 where each node represents a state from
which a specific symbol is emitted. For instance, the node labeled as A emits the
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symbol A. The lines connecting two nodes represent the probability of changing
states; i.e., the state transition probabilities are represented by each of the edges
connecting two states.
A B
C
Pr(A|B)
Pr(B|A)
Pr(A|
A) Pr(B|B)
Pr(
B|C
)
Pr(
C|B
)Pr(A|C)
Pr(A|C)
Pr(C|C)
Figure 2.3: The Markov process of the given sequence illustrated by a directed
graph
2.2 The receiver operating characteristic (ROC) curve
An ROC curve measure can be used to evaluate the discriminative performance of
binary classifiers in machine learning. By varying the discrimination threshold for
a binary classifier, the ROC curve measure can be obtained by plotting the curve
of true positive rate (sensitivity) versus false positive rate (1 - specificity). When
the ROC curve matches with the upper left corner of the ROC space, the best
performance would be achieved as this would yield 100% sensitivity and 100%
specificity. Moreover, the closer the ROC curve is to the upper part of the ROC
space, the better the performance of the classifier.
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Figure 2.4 shows ROC curves for 3 different predictors whereas the dotted line
shows the line that denotes the average AUC.
Figure 2.4: ROC curves for 3 different predictors
2.3 Area under the ROC curve (AUC)
Since an ROC curve is a two-dimensional depiction of classifier performance, and
in order to compare classifiers we might need to reduce ROC performance to
a single scalar value that represents the expected performance [23]. A common
method is to calculate the area under the ROC curve, abbreviated AUC. The value
of any AUC will always lie between 0 and 1 since the AUC calculates the portion
of the area of the unit square [(23)]. However, since random guessing produces the
diagonal line between (0, 0) and (1, 1) with an area of 0.5, no realistic classifier
should have an AUC less than 0.5. Hence, an AUC value close to 1 indicates better
performance [24]. Figure 2.5 shows the areas under two ROC curves, A and B
where classifier B has greater area and, therefore, better average performance.
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Figure 2.5: An ROC graph that shows the area under two ROC curves for two
classifiers A and B.
2.4 Hidden Markov Model (HMM)
A HMM is a model in which the system being modeled is assumed to be a
Markov process with unknown parameters. HMM builds a causal model for ob-
servation sequence O = (o1, o2, , on) by introducing corresponding ’hidden states’
q = (q1, q2, , qm). The parameters of the HMM are λ = (a, b, pi) where
′a′ is the
parameter for the transition model P (qt|qt−1) and ′b′ is the parameter for the obser-
vation model P (ot|qt). The hidden parameters are determined from the observable
parameters. The extracted model parameters can then be used to perform further
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analysis; for example, pattern analysis or feature subset selection.
For better understanding the HMM, let us consider an example of persons and
stick model. Assume there are N persons in a closed room (see Figure 2.6). Each
person is holding a number of colored sticks. The sticks are of M distinct color.
Now, each person throws the colored sticks, one after another, out of the room.
At this stage, the only visible outcome is the sequence (order) of colored sticks
received. We do not know who, out of N persons,) has thrown which colored
sticks.
Figure 2.6: The person and stick model
In this example, both the selection of a person and color are completely ran-
dom. The individuals are hidden from the view, making it a hidden process. The
overall process generates a sequence of colors/colored sticks, which forms the out-
put observation sequence. For this process, we do not know the sequence in which
a person is throwing the colored sticks, nor the sequence of persons throwing the
sticks. The output sequence is very much dependent on the transition probabili-
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ties between the various persons/states, and the choice of initial person/state at
the beginning. This example can be associated with a HMM, where the states
are hidden (like the persons in the example) and the output is the sequence of
observations.
2.5 Baum-Welch expectation maximization algorithm
The BaumWelch algorithm [(22)] is a specific case of a generalized expectation-
maximization algorithm that can compute maximum likelihood estimates and
posterior mode estimates for the parameters (transition and emission probabili-
ties) of a HMM, when given only emissions as training data.
It works as follows: For a given cell Si in the transition matrix, all paths to
that cell are summed. There is a link (transition from that cell to a cell Sj ). The
joint probability of Si , the link, Sj and can be calculated and normalized by the
probability of the entire string. Let us denote this as χ.
Then we calculate the probability of all paths with all links emanating from
Si and normalize this by the probability of the entire string. Let us denote this
as σ.
Finally we divide χ byσ. This is dividing the expected transition from the cell
Si to the cell Sj by the expected transitions from Si . As the corpus grows, and
particular transitions are reinforced, they will increase in value, reaching a local
maximum.
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Chapter 3
Existing Techniques
In the diagnosis of cancers, gene selection is widely used to select target genes.
Due to the high dimensions and relatively small number of samples of microarray
data, over-fitting is a common problem. One of the primary goals of gene selection
is to avoid this over-fitting problem [25]. In cancer classification, only informative
genes which are highly related to particular classes (or subtypes) should be selected
theoretically [26].
The primary challenge in microarray data analysis is to select informative
genes that clearly differentiate the given classes. In each experiment, since the
number of informative genes is very small compared to the total number of genes,
utilizing a better search technique is critical. We have divided such approaches into
two main categories: statistical approaches and artificial intelligence approaches.
Lazar et al. [27] and Saeyss et al. [28] presented a detailed discussion on filtering
techniques for feature selection in bioinformatics.
This chapter is organized as follows. Section 3.1 discusses the recent techniques
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that identified important genes using the statistical methods. In Section 3.2,
we describe the recent and popular techniques for gene selection using artificial
intelligence (AI) techniques.
3.1 Statistical approaches
The methods in the statistic approach rank (score) the discriminability of each
gene based on its own gene expression patterns. For the estimations of discrim-
inability, both parametric and nonparametric approaches for have been proposed.
The parametric estimation approaches evaluate the discriminability of genes
using a variety of statistical analysis, including signal-to-noise ratio (SNR), t-Test,
and least significant difference (LSD). Parametric estimation depends on exact
expression levels and the number of replicate samples. The statistical criteria are
based on the assumption that the data comes from some kind of distribution [25].
Each parametric approach puts different weights on the variance and number of
samples of the criteria. A gene is considered more informative if it possesses a
larger corresponding score [25].
3.1.1 Parametric approaches
Signal-to-Noise Ratio (SNR)
Each dataset comprises m samples and n genes. The gene expression data is
normalized by subtracting the mean (signal) and then divided by the standard
deviation of the expression value (noise) for each gene gi. Each sample is labeled
as (+1, -1) for classification e.g. normal or cancer. The following formula is used
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to calculate each gene’s ‘F ’ score.
F (gi) =
|µ+1(gi)− µ−1(gi)|
σ+1(gi) + σ−1(gi)
where µ and s denote the ‘mean’ and the ‘standard deviation’ respectively of
samples in each class (+1, -1) individually. These genes can then be ranked and
top n genes can be selected as the features.
t-Test
The t-Test evaluates whether the means of two groups are statistically different
from each other [25]. Since samples may be derived from different experiments
and may have different distributions in microarray data analysis, the unpaired
two-sample t-Test is often used. The discriminative power of the ith gene using
t-Test is calculated as
T (gi) =
|µ+1(gi)− µ−1(gi)|√
σ+1(gi)2
M+1−1 +
σ−1(gi)2
M−1−1
where M+ and M- are the sample sizes and µ and s are the respective mean
and standard deviation of samples in each class (+1, -1). These genes can be
ranked with a T score. Finally the top n gene sets can be selected as the features.
Least Significant Difference (LSD)
Also known as the Fisher criterion, LSD is a classical measure to evaluate the
degree of separation between two classes. It is a t-Test-like statistic. The score
for gene i is calculated as
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F (gi) =
|µ+1(gi)− µ−1(gi)|
σ+1(gi)2 + σ−1(gi)2
3.1.2 Non-parametric approaches
In contrast to the parametric approach, nonparametric approaches rank samples
of each gene using their expression level. These approaches punish the disorders
that tend to damage a perfect sample split. The smaller the score a gene receives,
the lesser the punishment. This means that a gene is more informative if it has a
smaller corresponding score.
Threshold Number of Misclassification (TNoM)
The basic assumption in TNoM is that an informative gene has different values
between the two classes. Therefore, these genes are separated using a threshold
value. In order to score the given gene and predict the unknown class, a decision
rule corresponding to a given expression level is used. TNoM looks to select the
values in order to minimize the number of errors:
Err(a, b|i) =
∑
k
λ {λ(i) 6= sign(a×G(i)k + b)}
TNoM(i) = mina,bErr(a, b|i)
Then the genes can be ranked based on TNoM score and top n genes can be
selected as the features.
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Minimum Distance to Modal Ranking (MDMR)
It first ranks all the sample values of a gene and then computes the minimum dis-
tance between these ranks and a modal rank. The ranking algorithm is described
by [29]. A score is defined as the minimum number of consecutive swaps needed
to arrive at a perfect split of two classes. A score of 0 represents the gene that
can split two classes exactly. The MDMR score is defined as
MDMR(i) =
∑
p∈−1
∑
q∈+1
h (xp − xq)
where h(x) is the indicator function
h(x) =

1, x > 0
0, x ≤ 0
Then the genes can be ranked based on MDMR score and top n genes can be
selected as the features.
Weighted Punishment on Overlap (WEPO)
The WEPO method was proposed by Chung et al. [30] to reduce possible loss
of information when using the TNoM or MDMR methods. WEPO introduces
the z-score into the rank swapping scheme because genes with identical ordered
expression data may not have the same discriminative power. For gene k, the ex-
pression levels of samples are first normalized via z-score to eliminate the problem
of scaling. The z-score is defined as
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Zki =
G(i)k − µi
MAD(i)
where µ represents the sample mean and MAD represents the mean absolute
deviation of gene k. The punished score of each gene is calculated by estimating
the overlapping regions of the two classes. The punishment is defined as
WEPO(i) =
∑
p∈+1
∑
q∈−1
ψ(zpi − zqi), ψ(z) =

|z|, z > 0
0, z ≤ 0
Principal Component Analysis (PCA)
PCA is a popular method used in multivariate data analysis to reduce the dimen-
sionality of the data and summarize the data in a parsimonious manner. It has
become a useful tool in the analysis of mircroarray data.
Assume we have the gene expression data of p genes for n samples. The goal
of PCA is to transform the p gene expression values to corresponding principal
comopnent scores. Since the rank of n× p matrix cannot exceed the minimum of
n and p, we expect that the top M principal component scores will convey most
of the sample information stored in the original p values.
Lets assume that the essential dimensionality of a microarray dataset has been
determined as M . Now we need to find a method that select q genes that can
preserve the original data structure. The goal is to determine a gene subset whose
first M principal compnent scores have the shortest square distance, denoted as
DIST 2, to the first M principal component scores of the original microarray
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dataset.
Let X and Xˆ represent the orginal dataset and the selected gene subset. Let Y
and Z˜ denote the (n×M) data matrix of top M principal component scores and
the M -dimensional approximation of q genes to the original data configuration
resepectively. The gene selection procedure is specified below:
1 Initially set q = p and compute the matrix of principal component scores Y .
Set Z = Y .
2 Obtain and store the principal component scores matrix by iteratively removing
each gene from Z.
3 Compute the square distance DIST 2 for each matrix and identify the gene xu
that yields the smallest DIST 2. Let us denote the corresponding matrix of
scores as Z˜u.
4 Remove gene xu. Set Z = Z˜ and goto step 2 with p − 1 genes. Repeat until
only q genes are left.
The above procedure will select the most informative genes from the gene
expression dataset.
3.2 AI approaches
Besides the above mentioned statistical approaches, researchers have used arti-
ficial intelligence approaches to select high impact genes from cancer datasets.
These approaches employ artificial intelligence techniques like neural networks,
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genetic algorithms, decision trees, random forests, support vector machines and
self organizing maps. In the subsequent sections, we will briefly describe how
these techniques are implemented.
3.2.1 Self-organizing maps (SOMs)
Tamayo et al. [31] stated that SOMs have a number of features that make them
particularly well suited to clustering and analysis of gene expression patterns.
Since they allow one to impose partial structure on the clusters, they are ideally
suited to exploratory data analysis [31]. This is in contrast to the hierarchical clus-
tering’s rigid structure and the Bayesian clustering’s strong prior hypotheses [31].
They also facilitate easy visualization and interpretation. The benefits of using
SOMs are that they have good computational properties, are easy to implement,
reasonably fast, and scalable to large data sets.
SOMs are constructed as follows. A geometry of “nodes” is chosen - for exam-
ple, a 3×2 grid. Starting randomly, then the nodes are mapped into k-dimensional
space that are then adjusted iteratively. In each iteration, a random data point P
is selected and the nodes are moved in it’s direction. The node closest to P, de-
noted as Np, is moved the most, while other nodes are moved by smaller amounts
depending on their distance from Np in the initial geometry. In this manner,
neighboring points in the initial geometry tend to be mapped to nearby points in
k-dimensional space. The process is repeated for m iterations.
The mapping of nodes, adjusted by moving points toward P, is calculated by
the formula:
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fi+1(N) = fi(N) + τ(d(N,Np), i)(P − fi(N))
The learning rate τ decreases with distance of node N from Np and with
iteration number i. The point P that is used at each iteration is determined by
random ordering of the n data points generated once and recycled as needed. The
function τ is defined by
τ(x, i) =
0.02T
T + 100i
for x = ρ(i) and τ(x, i) = 0
Otherwise, T is the maximum number of iterations if radius ρ(i) decreases
linearly with i.
3.2.2 Genetic Algorithms (GAs)
Based on the analogy with biology, GAs are adaptive search techniques, in which a
set of possible solutions evolves via natural selection [32]. Genetic algorithms have
been a popular choice of researchers for feature selection among high dimensional
datasets [32; 33; 34].
In genetic algorithms, a solution is represented by a finite sequence of 0’s and
l’s. This sequence is called a “chromosome”. In the application of GAs for feature
selection, each chromosome represents a subset of features i.e., the kth bit denotes
the presence or absence of the kth feature in the dataset. The algorithm manipu-
lates a finite set of chromosomes, called the population, in a fashion resembling the
mechanism of natural evolution. In this mechanism, the chromosomes are allowed
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to crossover (mate), and to mutate (change). The mating of two chromosomes
produces a pair of offspring chromosomes which are offsprings of their parents. A
mutation of a chromosome produces a near identical copy with some components
of the chromosome altered due to the mutation.
The optimization process is executed in cycles known as “generations”. A set
of new chromosomes (bit strings) ai is created through crossover, which is then
mutated and finally evaluated during each generation. Only a predefined number
of the best (strongest) chromosomes survive to the next cycle of reproduction due
to finite population size.
The population is capable of fast adaptations, despite its limited size, which
results in rapid optimization of the criterion function (score).
A high-level algorithmic description of the basic method was outlined by
Siedlecki et al. [34]. Though many variations of this basic method exist, their
description captures the primary characteristics of all GAs.
In the above algorithm f is the so-called fitness function and is calculated as
f =
n∑
i=1
f(ai)/n
Similar to the biological function of crossover, the genetic algorithms, that were
designed for modeling biological evolution, the crossover operator, crossover(a,b),
implements exchanges of information among chromosomes a and b. In particular,
if a chromosome is represented by a binary string (as in feature selection), crossover
can be implemented by randomly choosing a point, called the crossover point, at
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Algorithm 1 : Basic Genetic Algorithm pseudo code
1: Construct an initial population set
∏
= {ai}i=1,...,n
2: for i← 1 to Number of generations do
3: Initialize mating set M ← ∅ and offspring O
4: for j ← 1 to n do
5: Add f(ai)/f copies of ai to M
6: end for
7: for j ← 1 to n/2 do
8: Select a pair aj and ak from M and do O = O ∪ crossover(aj, ak) with
probability Pc
9: end for
10: for i← 1 to n do
11: for j ← 1 to d do
12: Switch the jth bit in ai ∈ O with probability Pm
13: end for
14: end for
15: Update the population
∏ ← Combine(∏, O)
16: end for
which two chromosomes exchange their parts to create two new chromosomes
[34]. For instance, given two strings, 0010− 0101 and 1011− 1010, the crossover
operator cut them in the middle. The result, crossover(00100101, 10111010) will
produce two new chromosomes i.e., 0010-1010 and 1011-0101.
Mutations increases the variability of the population. In the above example,
involving bit strings, a mutant can be created by changing at random one or more
bits in the structure i.e., 0010-1010 can be mutated as 0010-1011 (last bit inverted)
or 1010-1010 (first bit inverted) or any other bit(s) can be inverted to form a
mutated copy (the hyphens are used in the notation for ease of understanding).
The new population if formed by combining the old population and the off-
spring(s), the method is symbolically denoted as H ← Combine(H,O). There
are a number of possible implementations of this procedure, ranging from more
radical, like H ← O i.e., the new population comprises the offspring(s) only, to
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less restrictive, like “select n best chromosomes from H and O” which is mostly
used.
The population size, crossover rate and mutation rate are common for all
implementations. The crossover rate is the probability of accepting an eligible pair
of chromosomes for crossover. The mutation rate is the probability of switching
bits in the chromosomes. The crossover rate usually assumes high values, close or
equal to one, while the mutation rate is typically small (1 to 15%) [34].
The fitness function is another key element in the efficient application-oriented
version of the genetic algorithm. However, the execution and performance of
genetic search is also determined by a number of parameters, some of them specific
for distinct implementations of genetic algorithms.
3.2.3 Random Forest Gene Selection (RFGS)
Random forest is a classification algorithm that was developed by Leo Breima [35]
and uses a combination of classification trees. Each of the classification tree is
built using a bootstrap sample of the data, and at each split the candidate set of
variables is comprised of a random subset. Thus, random forest uses both bagging
and random variable selection for tree building.
The pseudo code for this approach is outlined in Algorithm 2 where X is the
cancer’s gene expression data (containing S samples G and genes) and the Y S is
the label of each sample. The output of the algorithm is a list of top Z genes.
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Algorithm 2 : The pseudo sode of the Random Forest Gene Selection
method
Input: X = { xSG, Y S } , S = 1, . . . , s, , G = 1, . . . , g, , Y S = { -1, 1 }
Output: n top genes
1: Begin
2: for i← 1 to S do
3: do normalize X
4: end for
5: end
6: for I ← 1 to N do
7: while (All genes assigned completely) do
8: Randomly assign all genes into M groups
9: end while
10: for J ← 1 to M do
11: Build up a decision tree on each group
12: Mark the root of each group
13: end for
14: end
15: end for
16: end
17: Rank gene following the number of marks for every gene
18: Select the top Z genes from the ranking list
19: Confirm the genes with biological evidence from public resources
20: Calculate the average biological genes found in the top Z genes
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3.2.4 Support Vector Machines (SVMs)
SVMs were introduced by Vapnik et al. [36] and successively extended by a
number of other researchers. Their remarkable robust performance with sparse
and noisy data makes them a good choice in a number of applications from text
categorization to protein function prediction [37].
SVM is a learning machine based on statistical learning theory [20]. When
used in classification, SVM separates binary labeled training data by constructing
a hyperplane, which separates class members from non-members. The training
set consists of two sets of data; one contains data known to be in a certain class,
i.e. genes that have a common function, whereas the other contains data that
does not. The genes that are in the class are labeled positively and those which
are not in the class are labeled negatively.
From this data, SVM can learn to distinguish between expressions of genes
in the training set that are in the class and those of genes that are not. They
can then classify new genes as being members or non-members using the infor-
mation already learnt about which gene expressions correspond to which class. A
hyperplane that has maximal distance from members to non-members is called
a maximum margin hyperplane. When the data is not linearly separable, SVM
maps the data into a higher dimensional space,called a feature space, and de-
fines a separating hyperplane. The kernels of the SVMs automatically realize a
non-linear mapping to a feature space. The hyperplane found by an SVM in the
feature space corresponds to a decision boundary in the input space.
29
Let xi, where i=1,2,. . .,M , be feature vectors of a training set X that belong
either of the to two classes ω1 or ω2. Using this training data, SVM finds an
optimal hyper-plane with the maximum margin that can separate the unknown
input patterns into the 2 classes. Since many hyperplanes separating the feature
vectors are possible, SVM finds the one that has maximum margin and better
generalization performance for classification.
g(x) =wTx + w0 = 0
Since SVM is basically a linear classifier that classify linearly separable data, there
may be scenarios where the feature vectors might not be linearly separable. To
overcome this issue, kernel trick is used.
The original input space is mapped into a high-dimensional feature space using
kernel functions where it becomes linearly separable. The performance of an
SVM classifier is dependent on the choice of a proper kernel function. Different
kernel functions have been employed for different classification tasks. Some of the
popular kernel functions and their mathematical forumlae are mentioned below.
Polynomial kernel with degree d
K(xi , xj) = (γ x
T
i xj + 1 )
d , γ ¿ 0
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Radial basis function kernel
K(xi , xj) = exp (- γ ‖ xi - xj ‖2),γ ¿ 0
Sigmoid kernel function (also called known as Multi Layer Perception Kernel
or Hyperbolic Tangent Kernel)
K(xi , xj) = tanh ( γ x
T
i xj + r )
Gaussian kernel function
K(xi , xj) = ‖ xi - xj ‖ σ 2
In above formulae, γ, σ, r and d are adjustable kernel functions which are adjusted
based on the data
3.2.5 Artificial Neural Networks (ANNs)
Neural networks are made up of interconnected artificial neurons that mimic hu-
man brain processing. The interconnection links between neurons carry certain
weights. Each neuron’s output is determined by using an activation function such
as sigmoid and step. In case of neural networks that are trained with training
patter of known classes, they are called supervised learning NN.
The supervised learning process of the neural network consists of a unique
input signal and corresponding desired output signal. The network is trained
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until it reaches a stable state where the synaptic weights doesnt change and maps
to their corresponding output.
The encoding of neural network is composed of two parts; a binary string and
a weight matrix. The binary string is used to encode the input features, where
the value of each bit is 1 or 0 and it’s length is equal to the maximum number of
input features. Each bit in the string corresponds to a feature i.e., ‘1’ indicates
presence of a feature, while ‘0’ indicates absence of the feature.
Since an input feature corresponds to an input node in neural network, the
binary string also represents whether the corresponding input nodes exists. The
connection weights of the neural network are specified through the weight matrix
that has adimension of (m+ h+ n)(m+ h+ n). The connection weight from the
jth node to the ith node is denoted by wij. Since there is no connection from
the higher-numbered node to the lower-numbered node, only half of the matrix is
required. wii denotes the bias of the i
th node.
The evaluation of fitness is defined by
fitness = 1 - E - P
where E is the error rate of classification, P is the penalty factor for the
number of a feature subset
The error rate of classification is given by
E =1
T.n
∑T
t=1
∑n
i=1 (Yi(t)− Zi(t))2
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where T is the number of training samples, n is the number of output nodes,
Yi(t) and Zi(t) are actual and desired outputs of node i for sample t.
The penalty factor for the number of a feature subset is defined by
P = u . M
where M is the number of selected features, u is a penalty coefficient which is a
small user-defined parameter
Fitness calculates the individual selection for the next generation. First, the n
parent individuals and the n child individuals are sorted together according the
fitness. Then, the best n individuals are selected from them.
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Chapter 4
Literature Review
Through selective reference to some of the existing literature, this chapter pro-
vides a clearer understanding of different methods that have been used in the
identification of important genes from high dimensional datasets.
Feature selection in high dimensional datasets is the application area in this
thesis. Therefore, an extensive review of the literature is performed focusing on
those researches that addresses our application area. We present a review of some
of the key papers that have been highly influential to the application area. Most
of the papers attempted to solve the reported limitations of these techniques while
focusing on feature selection. Therefore, after describing the findings of each of
the papers reviewed, we report the limitations of each of the respective techniques.
This chapter is organized as follows. Some of the basic statistical approaches
are discussed in Section 4.1. In Section 4.2, we discuss some advances statistical
approaches employed for gene selection in high dimensional datasets. Section
4.3 enlists some of the biological approaches in the said area. In Section 4.4,
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some of the approaches that employed artificial intelligence for gene selection are
discussed. A summarized view of all the approaches is presented in Section 4.5
4.1 Basic Statistical Approaches
Among the existing methods that are based on extensive data analysis, the princi-
pal component analysis (PCA) [38], t-test [39], Mann-Whitney U test, Chi-squared
test are worth mentioning. PCA is efficient if the distinctive genes are linearly
related. To enable the PCA to deal with a non-linear relationship, kernels are
deployed before using the PCA. Therefore, PCA is actually used to find the linear
relationship among the genes after transforming the data using the kernel tech-
niques. Thus, PCA still remains sensitive to dimensionality and is also complex.
Furthermore PCA is directly dependent upon the correlation of each gene. The
t-test is a parametric test based on the prior assumption of data distribution. In
cases of wrong assumption of the distribution, the t-test looses important genes.
Another limitation of t-test is that it is directly dependent on the standard de-
viation of the expression data. Moreover, both PCA and t-test are sensitive to
scaling of the data. Unlike t-test, the Mann-Whitney U-test is a non-parametric
test that assesses whether the distributions of two samples of observations come
from the same distribution or not [40].
4.2 Advanced Statistical Approaches
Other than the previously mentioned basic statistical methods, there are studies
that attempt to better understand the genes and find out their linkage with breast
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cancer using advanced statistical methods.
Nguyen et al. [41] reduced the dimensions of gene space using Multivariate
Partial Least Squares (MPLS). Then either Polychotomous discrimination (PD)
or Quadratic Discriminant analysis (QDA) technique was used to select the genes
based on the corresponding gene’s mean square error (MSE). One disadvantage
of using PD is in the case of quasi-complete separation in the data which is
burdensome and usually results in poor classification.
Lee et al. [4] proposed a hierarchical Bayesian model for gene selection by
employing hidden variables and using a Bayesian mixture prior to performing the
variable selection. By assigning a prior distribution over the dimension (number of
significant genes) of the model, the size of the model is controlled. To simulate the
parameters from the posteriors, it uses a combination of truncated sampling and
Markov Chain Monte Carlo (MCMC) based computation techniques. However,
since they used a prior distribution, it might result in an unstable algorithm
convergence in case of high-dimensional or highly collinear covariates (related
genes). Furthermore the algorithm converge is slow due to the aforementioned
reasons [42].
Hedenfalk et al. [1] applied hierarchical clustering to group the similar patterns
and found that tumors from individual patients/families did not mix with tumors
from BRCA1 and BRCA2 mutation carriers, and remained clustered within the
groups. It was shown that gene expression profiling can discover novel classes
among BRCAx tumors, and differentiate them from BRCA1 and BRCA2 tumors.
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However, the number of selected genes is still quite large (51).
Zhou et al. [43] investigated Bayesian gene selection using the logistic regres-
sion model. Three different techniques were used for the identification of posterior
distribution of the selected genes, namely, Akaike information criterion (AIC), the
Bayesian information criterion (BIC) and the minimum description length (Mdl)
principle. These proposed methods were tested on different datasets including
hereditary breast cancer dataset from Hedenfalk [1]. The experimental results
showed that the proposed methods were effective in finding some genes that were
consistent with the contemporary biological knowledge.
4.3 Biological Approaches
There are various studies attempting to identify important genes in a high di-
mensional dataset using pure biological methods like DNA microarray analysis,
gene expression analysis etc. This approach is by far the most expensive and time
consuming due to the following reasons. The tests are conducted on the actual
blood samples from the breast cancer patients. Hence, the process of identifying
patients, getting their consent for sample donation, timely administration of drugs
to these patients and collecting the blood samples is a very lengthy process that
requires a large amount of time. Moreover, these analysis are performed under
the supervision of experienced biologists in biological laboratories. All of these
factors make this approach quite expensive and time consuming. Some of the
popular biological approaches are discussed below.
Veer et al. [44] used DNA microarray analysis on primary breast tumors of
37
117 young patients, and applied supervised classification to identify a gene ex-
pression signature strongly predictive of a short interval to distant metastases in
patient without tumor cells in local lymph nodes at diagnosis. They also estab-
lished a signature that identities tumors of BRCA1 carriers. This gene expression
profile was claimed to outperform all contemporary used clinical parameters in
predicting diseases outcome. They also provided a strategy to select patients who
would benefit from adjuvant therapy. Sørlie et al. [45] found that the prognostic
impact of the 231 markers, published by Veer et al. [44] on the Norwegian cohort,
performed less well (47%) in predicting recurrences within 5 years.
Honrado et al. [46] discussed the identification of a discrete number of genes
able to predict whether a breast tumor was associated with a germ-line mutation
in BRCA2 or BRCA2 and proposed it could prove helpful. The contemporary
criteria for the selection of patients for BRCA1 and BRCA2 analysis was only
family history. They argued that this criteria was unspecific due to the fact that
around 70% of the studied families were not linked to either of these two genes.
However, the identification of the genes somatically altered in BRCA1 and BRCA2
associated tumors opened the opportunity to identify new molecular drug targets
specific for these hereditary cases.
Parvin et al. [47] described a novel workflow for the discovery of genes that
participate in the breast carcinogenesis process. Genes, whose expression are
lightly correlated with BRCA1, BRCA2, and other genes, were identified from
public data in the Gene Expression Omnibus (GEO) database [GEO:2012:Online].
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Then the genes were tested in the laboratory settings to identify which of these
genes regulate the same processes as do BRCA1 and BRCA2. Eight genes were
found to impact the homologous recombination among the first nine tested genes.
4.4 Artificial Intelligence Approaches
Computers are powerful machines that can perform complex calculations in mere
minutes. Moreover, no working lab or experienced biologists are required to an-
alyze a dataset. Different algorithms can be used to analyze the same dataset
yielding different results. These are some of the factors that have made this ap-
proach very popular over the last few decades. Some of the popular researches
that employed this approach are discussed below.
Kim et al. [48] explored all the pairs, triads, quadruples and quintets of genes
and identified their predictive power through strong feature sets algorithm. They
assessed the predictive ability of their feature sets by using perceptrons owing
to the small amount of data they required for design relative to more general
classifiers. 20 genes that appeared most often in the lists of strong performing
gene sets in different variable subset sizes, were summarized in separate tables for
various classifications.
Qizhong [5] proposed a new method of gene selection and classification by using
nonlinear kernel support vector machines (SVM) based on recursive performance
elimination (RFE). It used two publicly available datasets; Hedenfalks heredi-
tary breast cancer dataset and Acute lymphoblastic leukemia/Acute myelogenous
leukemia (ALL/AML) dataset. A list of twenty strongest genes is computed by
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using non-linear kernel SVM-RFE from both the datasets.
Raza et al. [20] used two methods, namely multivariate permutation test
(MPT) and significant analysis of microarray (SAM), to select significant genes
for feature selection. Then support vector machines (SVM) are applied with
polynomial, radial and linear kernels to classify the data. The results showed that
all the samples were classified correctly and 100% accuracy rate was achieved
among BRCA1- BRCA2 and BRCA1-sporadic. However, the misclassification
ratio may be increased if testing and training are done without feature selection
due to thousands of genes and fewer samples. This may result in the selection
of irrelevant genes that will affect the testing accuracy and will result in low
classification accuracy.
4.5 Approaches Summary
A summarized tabular view of the above mentioned approaches and the techniques
employed is listed in Table 4.1
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Table 4.1: List of approaches, techniques employed and authors for gene selection
in high dimensional datasets.
Approach Type Techniques Authors Reference
Advanced Statistical
MPLS + (PDA |QDA) Nguyen et al. [41]
Hierarchical Bayesian model Lee et al. [4]
Hierarchical Clustering Hedenfalk et al. [1]
AIC, BIC, MDL Zhou et al. [43]
Biological
DNA microarray analysis Veer et al. [44]
Gene expression analysis Honrado et al. [46]
Laboratory settings Parvin et al. [47]
AI
Perceptrons Kim et al. [48]
SVM + RFE Qizhong [5]
MPT + SAM + SVM Raza et al. [20]
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Chapter 5
The Proposed Hybrid Method
In this chapter, we describe our proposed hybrid method that comprises a multi-
pass feature selection. In pass one, we rank all genes and determine the highly
ranked genes one-at-a-time. In the second pass, we investigate the interrelation-
ship amongst the genes using a Hidden Markov Model (HMM) to find the best
subset of genes among the ranked genes. Details of these passes are described
in the subsequent sections. Figure 5.1 shows the overall working of the proposed
method and the different operations in each pass. In Section 7.2 discusses the
selected dataset in detail.
This chapter is organized as follows. In Section 5.1, we discuss the ranking of
the genes in the dataset using AUC measure. Section 5.2 describes the gene subset
selection from the highly ranked genes using HMM. In Section 5.3, we describe
the working of pass 1 and pass 2 with the help of a small geneset example for
better understanding.
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Figure 5.1: The proposed method
5.1 Ranking of genes using AUC
All the genes of the training set were ranked using the first step of Mamitsuka’s
ROC [49]. In a previous study, Hassan et al. [40] discussed that this is equivalent
of the Mann-Whitney U statistic normalized by the number of possible pairings of
positive and negative values. They described that the AUC actually represents the
probability that a randomly chosen positive example is correctly rated (ranked)
with greater suspicion than a randomly chosen negative example [40].
Let us consider a training gene expression dataset G of r records (pa-
tients/samples), where each record comprises n gene expressions: g1, g2, g3, . . . , gn.
Each of the n genes of a record has a differing discriminative power that is re-
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flected by its respective AUC. We calculate this power by plotting the ROC curve
for each gene paired with the mutation type i.e., (gi,Mi), where 1 ≥ i ≥ n and
Mi ∈ {BRCA1, BRCA2}. We calculate the AUC of the ROC curve and order the
genes based on their respective AUCs. The AUC measures discriminative power
of genes, i.e., their ability to correctly classify those with and without the disease
[50]. Therefore, a high rank of a gene is an indicative of its high likelihood to be
associated with BRCA1 or BRCA2 mutation.
This process begins by calculating the AUC for each gene as described below:
1. Select the gene
2. Sort the gene expression with the class level. This class level is the actual
value when calculating the AUC score.
3. Calculate AUC
(a) For the predicted value, assign +1 incrementally, from the first sample
till the last and calculate the AUC for each. (Start by assigning a +1
to the first sample. Then calculate the different measures like TP, FP,
Sensitivity, and Specificity for the actual value and the predicted value
and calculate the AUC. Next assign +1 to the first 2 samples, calcu-
late the measures and the AUC. Repeat until all samples have +1 as
their predicted value, calculate the different measures and calculate the
AUC. Finally select the maximum AUC among all the AUCs calculated
for various threshold settings)
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4. Goto step 1 and select the next gene.
Each gene was ranked according to the scores computed from the ROC curve
of the pair of the corresponding gene and the class label as previously described.
Comparatively less ranked genes are filtered out by using a threshold level to the
AUC scores. For our experiment in this research, we used two threshold values i.e.,
0.8 and 0.85 where 0.8 was the least restrictive whereas 0.85 was the most. The
best results were achieved by setting the threshold value to AUC ≥ 0.8. Moreover,
we knew that random guessing would yield an AUC value of 0.5, hence the selected
threshold value should be greater than 0.5. Furthermore, some previous studies
[40; 49] had already used AUC measure to preselect top ranked genes, thus, we
got an idea for the minimum threshold from their research as well. Figure 5.2
shows the pictorial view the operations involved in the calculation of calculating
the AUC for all the genes.
5.2 Gene subset selection using Hidden Markov Model
This pass begins by receiving a list of important genes that have an AUC ≥ 0.8
from the previous pass. In our HMM, each state represents a gene. We start
training the hidden Markov model and calculate the two-way Wilcoxon Rank-
sum measurement [51] for each state (gene) with the other state (gene).
In order to select the best possible model that fits the given data, we use the
well-known Baum Welch expectation maximization algorithm [22]. It runs in a
loop either for 50 cycles or until the log likelihood value of the new model is less
than the log likelihood value of the previous model (indicating no better model
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Figure 5.2: Pass 1 - Ranking of genes using AUC
possible). This ensures that the best model is selected among all the possible
models that fit the given data. After each cycle, the emission, transition and
initial probability (pi) matrices are updated so that the next model is better than
the current model as shown in Figure 5.3.
While building the model, the p-value for the two-way Wilcoxon ranksum
measurement of each gene with all other genes are calculated and saved in a
separate matrix referred to as the p-value matrix. Every cell in the matrix is the
numerical value of the ranksum measure between two genes’ expression vectors
(expression profile values). Hence, if we have 20 genes, the matrix will have 20
rows and 20 columns (20x20) where each cell holds the ranksum measure of each
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gene with all the other genes. The proposed null hypothesis (Ho) for comparing
any two genes is that ”two genes are similar if they have a p value greater than
0”. Conversely, the alternate hypothesis (H1) is that “two genes are distinct if
the p value is 0”.
Figure 5.3: Building HMM
Once the best model has been selected, we study the outputs of the hidden
Markov model especially the emission probability matrix and the p-value matrix.
We identify all rows and columns that have non-zero values and study the pattern
in which the values are spread over the matrix. Then we compare the values with
the null hypothesis to identify the genes that are distinct as well as those genes
that are common. Figure 5.4 shows the p-values matrix and one common and one
unique gene. In case of common genes i.e., genes whose p-values are non-zeroes
and their patterns are similar in the p-value matrix, we select the gene that has
the highest AUC among them.
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Figure 5.4: Analyzing the p− value matrix
5.3 A small geneset example
For better understanding the various steps in pass 1 and pass 2, let us consider a
small geneset of 5 genes each with 10 expression values listed in Table 5.1. Each
gene has a class level associated with it; +1 indicate BRCA1 mutation while -1
indicate BRCA2 mutation. Now we input this geneset into the first pass.
Table 5.1: A sample geneset
Gene1 Gene2 Gene3 Gene4 Gene5 Class
0.31 0.63 0.32 0.64 0.91 +1
0.65 0.90 0.14 0.12 0.38 -1
0.88 0.14 0.09 0.97 0.56 -1
0.29 0.93 0.79 0.39 0.48 -1
0.17 0.80 0.84 0.11 0.81 +1
0.23 0.77 0.63 0.83 0.31 -1
0.54 0.10 0.77 0.57 0.17 +1
0.80 0.28 0.91 0.47 0.26 +1
0.14 0.79 0.73 0.17 0.97 +1
0.60 0.18 0.81 0.49 0.16 +1
5.3.1 Ranking of genes using AUC
In this pass, the AUC for all the genes is calculated using the following steps:
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Step 1 Select the first gene and sort it according to its expression values with
the class label
Step 2 Then assume the predicted values for this gene class by assigning +1 to
the first sample and -1 to the rest of the samples. This is threshold 1 i.e.,
one positive label while the rest are negative labels.
Step 3 Now calculate the different measures like TP , FP , sensitivity and
specificity for the actual values and the predicted values and then calculate
the AUC .
Step 4 Next modify the predicted values of this gene’s class by incrementing 1
to the threshold i.e., the first two samples are assigned +1 while the rest are
considered -1.
Step 5 Again calculate the different measures and then calculate the AUC for
this new threshold. After calculating the new AUC value compare it with
the old AUC value for the previous threshold and pick the max AUC.
Step 6 Alter the threshold until all the samples have the same class. Now the
AUC value of this gene is the maximum possible value for all the thresholds.
Step 7 Repeat the above mentioned steps for the next gene.
Figure 5.5 explains the first four steps for calculating the AUC for a single gene
by varying the predicted class threshold. Steps 5 and 6 ensure that the maximum
value of AUC, among all the calculated AUC values for the various thresholds,
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Figure 5.5: Calculating the AUC for a single gene
is selected. Step 7 ensures that the process for calculating the maximum AUC
for a gene that has been specified is repeated for all the other genes. After the
calculation has been completed for the whole geneset, we will have a dataset in
which each gene will have a respective AUC score indicating it’s strength. Finally
we discard the less important genes by setting a threshold value of AUC ≥ 0.8.
This ensures that only the most powerful genes are selected and transferred for
the second pass. Table 5.2 contains the genes that have an AUC value above the
threshold and are used in the second pass. The AUC value of each gene is listed
in the last row of Table 5.2.
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Table 5.2: The filtered geneset and the AUC value for each gene
Gene1 Gene2 Gene3
0.31 0.63 0.32
0.65 0.90 0.14
0.88 0.14 0.09
0.29 0.93 0.79
0.17 0.80 0.84
0.23 0.77 0.63
0.54 0.10 0.77
0.80 0.28 0.91
0.14 0.79 0.73
0.60 0.18 0.81
0.91 0.87 0.80
5.3.2 Gene subset selection using Hidden Markov Model
This pass starts when the list of genes has been filtered in pass 1. The operations
in this pass are mentioned below:
Step 1 Initialize the emission, transition and initial probability (pi) matrices ran-
domly
Step 2 Start Baum-Welch expectation maximization algorithm for n number of
cycles
Step 3 Start training the HMM
Step 4 Once the HMM has been trained, check whether this model is better than
the previous model based on log likelihood value
Step 5 If the current model is better, update the matrices that were randomly
initialized in step 2. If the current model is not better than the previous
51
model, then stop
Step 6 Goto step 3 and train a new HMM with the updated matrices
Once the above mentioned process is completed, we get a HMM that best
fits the given data. An example of a HMM that fits the geneset example data
listed in Table 5.2 is shown in Figure 5.6 where we have 3 genes and the emission
probability shown for each gene.
Figure 5.6: A sample HMM for geneset shown in Table 5.2
In order to understand the use of p-values and the other matrices in analyzing
the important genes, let us consider a sequence as ‘AABABACDDAABBCCDD’. Figure
5.7(a) shows the Markov process/model (λ) for this sequence using four distinct
states, and the corresponding state transition matrix. Figure 5.7(b) shows another
HMM (λ∗) that uses five states and the corresponding transition model for the
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same sequence. Since, in HMM (λ∗), we have considered the same symbol/feature
‘A’ twice, the observation emission probability for ‘A’ from one of the states
assigned for ‘A’ will be zero. Hence, analysis of the transition matrix Z∗ reveals
that there are at least four unique symbols while the remaining one (out of five
states) can be considered as redundant. A similar analysis can be done using the
state transition matrix Y ∗. By identifying the redundant features amongst the
pre-selected features we obtain the most discriminative feature subset.
In the above mentioned example, we have simple characters like ‘A’, ‘B’ etc and
we can easily identify the recurring elements because each character is a scalar
value. However, the pattern (same rows, columns) is helpful in identifying the
recurring and/or unique characters.
Now when we try to implement the above mentioned scenario in our gene
expression dataset, we have to consider that we have array of genes, in place of
single characters, that we can consider as a vector. Therefore, for comparing the
two vectors (genes), we have used two-way Wilcoxon Rank-sum measurement [51]
of each gene with all the other genes. Similar to the characters in the string
example, the patterns (rows, columns) will be helpful in identifying the unique
genes.
In conclusion, after the HMM is modeled, we analyze the p-value matrix to
identify the list of unique and common genes. As mentioned earlier, the null
hypothesis is that the genes with a p− value > 0 are common whereas the genes
whose p value is 0 is unique. Now to identify the cluster (group) of the common
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A B C D A A B C D
2     3     1     0
2     1     1     0
2     1     1     0
2     1     1     0
Y  =  116
2     2     3     1     0
2     2     3     1     0
2     2     1     1     0
0     0     0     1     2
Y*  =  116
1     1     0     0     2
6     0     0     0
0     4     0     0
0     0     3     0
0     0     0     4
Z  =  117
6     0     0     0     0
0     0     0     0     0
0     0     4     0     0
0     0     0     3     0
Z*  =  117
0     0     0     0     4
(a) (b)
λ λ*
123
               
               
0     0          2
1 0 0 2
Figure 5.7: (a) A HMM structure for the sequence “AABABACDDAABBCCDD”
where each state represents a unique symbol, (b) A HMM structure for the same
sequence where an additional state for the symbol is introduced assuming that
the symbol ‘A’ represent two unique symbols. Y (Y*) and Z (Z*) represents the
state transition and observation emission probabilities matrices respectively in
each case of HMM structure.
genes, we analyze the patterns in the p-value matrix. Figure 5.4 shows the analysis
of the matrix for identifying the genes.
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Chapter 6
Existing literature results
In this Section, we discuss the results that have been achieved by some of the
studies we discussed in Chapter 4. As previously mentioned, a lot of work has
been done in the feature selection in dimensional datasets has been done in the
last decade. We discuss the results that were achieved by some of these studies.
This will help the reader when we compare the list of genes identified by our
method with the different list of genes identified by the existing studies.
This chapter is organized as follows. Results from Hedenfalk et al. [1] are
listed in Section 6.1. The results of Storey et al. [2] are discussed in Section 6.2.
Section 6.3 has the results from Zhou et al. [3]. In Section 6.4, the results from
Lee et al. [4] are listed. Section 6.5 discusses the results from Qizhong [5]. The
results of Xiong et al. [6] are listed in Section 6.6.
6.1 Results of Hedenfalk et al. [1]
Hedenfalk et al. [1] identified 51 genes that can be used to differentiate BRCA1,
BRCA2, and sporadic cases of primary breast cancer shown in Table 6.1.
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Table 6.1: The list of 51 genes identified as important by Hedenfalk et al. [1] with
their respective IMAGE clone IDs
IMAGE Clone ID
897781 51209 42888
139354 949932 38763
809981 784830 366824
841617 26082 840702
823940 46019 564803
29054 247818 137638
810057 214731 73531
950682 236055 32231
26184 197176 274638
344109 566887 234150
36775 725680 701481
341130 823775 838568
417124 293104 31842
429135 46182 666377
44666 307843 50413
340644 366647 345645
246194 212198 810551
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6.2 Results of Storey et al. [2]
Storey et al. [2] processed the breast cancer dataset and identified a list of impor-
tant genes. The top 45 genes identified as important are listed in Table 6.2
Table 6.2: The list of top 45 genes identified as important by Storey et al. [2]
with their respective IMAGE clone ID
IMAGE Clone ID
566887 814270 838568
212198 46019 365147
42888 26184 75009
784830 344109 295831
366824 236055 136769
950682 548957 812227
51209 810057 133178
32790 841617 841641
897781 898123 49788
247818 31842 197176
82991 366647 23014
809981 236129 291057
29054 711680 134748
293104 293977 127099
949932 840702 36775
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6.3 Results of Zhou et al. [3]
Zhou et al. [3] identified a list of 20 important genes from breast cancer dataset
that are listed in Table 6.3
Table 6.3: The list of 20 genes identified as important by Zhou et al. [3] with
their respective IMAGE clone IDs
IMAGE Clone ID
26184 841617
47542 309583
823940 137638
44180 247818
47884 307843
183200 160793
21652 46019
139354 725680
809981 366647
214068 26082
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6.4 Results of Lee et al. [4]
Lee et al. [4] identified a list of 27 “strongly significant genes for the classification
of BRCA1 versus BRCA2 or sporadic” that are listed in Table 6.4 with their
respective IMAGE Clone IDs.
Table 6.4: The list of 27 genes identified as important by Lee et al. [4] with their
respective IMAGE clone IDs
IMAGE Clone ID
897781 73531
823940 950682
26184 47681
840702 46019
376516 307843
47542 548957
366647 788721
293104 843076
28012 204897
212198 812227
247818 566887
26082 563598
667598 324210
30093
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6.5 Results of Qizhong [5]
Qizhong [5] listed 20 genes as important that are shown in Table 6.5.
Table 6.5: The list of 20 genes identified as important by Qizhong [5] with their
respective IMAGE clone IDs
IMAGE Clone ID
667598 293104
47884 247818
137638 810899
897781 73531
823940 28012
81331 46019
366824 366647
307843 44180
212198 32790
564803 843076
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6.6 Results of Xiong et al. [6]
Xiong et al. [6] identified a list of 20 important genes listed in Table 6.6.
Table 6.6: The list of 20 genes identified as important by Xiong et al. [6] with
their respective IMAGE clone IDs
IMAGE Clone ID
175123 179804
714106 563444
210887 345423
29054 246194
36775 23014
21652 51209
233721 341130
666377 345645
50413 32790
6.7 Other studies
In addition to the above discussed studies, there are other researches that identified
a list of important high-impact genes by Kim et al. [48], Zhou et al. [43] and
Jazaeri et al. [52] among others.
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Chapter 7
Experiments and Results
This chapter discusses the experimental setup for this research, the dataset that
was used and the results that were achieved from our proposed hybrid method.
This chapter is organized as follows. Section 7.1 discusses the experimental setup.
In section 7.2, we present a brief overview of the selected dataset. Section 7.3
discusses the list of genes that were identified as important by our hybrid method.
7.1 Experimental Setup
The proposed hybrid method was programmed using MATLAB and was executed
on a Intel Core i5 machine with 4 GB RAM. The execution time of the program
took about 50-60 minutes for writing the output files. These files were then ana-
lyzed to identify the important gene set. Each of the gene in the identified geneset
was then searched on Database for Annotation, Visualization and Integrated Dis-
covery (DAVID) [7] to identify the list of associated diseases. In addition, several
major medical databases like PubMed NCBI [53] and search engines like Google
were also used to search for the diseases associated with the identified geneset.
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7.2 Dataset
The data used in this research came from the breast cancer cDNA microarray
experiment by Hedenfalk et al. [1]. Data were collected from the blood of patients
with primary breast cancer who had a family history of breast or ovarian can-
cer, or both, that was compatible with a dominant mode of inheritance. Biopsy
specimens of primary breast tumors from patients with germ-line mutations of
BRCA1 (seven patients) or BRCA2 (eight tumors from seven patients) were se-
lected for analysis. Gene expression profiles were generated for each sample and
were used to determine which of the genes expressed by the tumors correlated with
the BRCA1-mutation-positive tumors and the BRCA2-mutation-positive tumors.
Lastly 3226 genes were selected that were expressing distinctly between the two
tumors.
7.3 Results
Since our dataset was extremely small, we ran the hybrid method twice to find
the important genes. In the first run, we did not use any validation technique and
got a list of genes that were identified as important. In the second run, we used
leave one out cross validation (LOOCV) to validate the small dataset. Since we
had only 15 BRCA1 vs. BRCA2 patients, the LOOCV technique resulted in 15
different lists of genes that were identified as important by the hybrid method.
In order to identify only the most important genes, we selected only those genes
that were repeated in all or most of the 16 lists (1 without and 15 with LOOCV).
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Figure 7.1 shows the list of genes identified without LOOCV, and for each
iteration of LOOCV.
Figure 7.1: List of genes without and with LOOCV
Table 7.1 shows the list of selected genes with their respective IMAGE clone
ID, Entrez Gene ID and the AUC value for each gene.
Table 7.1: The list of genes selected using the hybrid of AUC-HMM method with
their respective IMAGE clone ID, Entrez Gene ID and the AUC value for each
gene
IMAGE Clone ID Entrez Gene ID Entrez Gene Symbol AUC
value
36775 3030 HADHA 0.964
823940 10140 TOB1 0.929
949938 1471 CST3 0.929
73531 23479 ISCU 0.929
34357 60 ACTB 0.911
23019 2778 GNAS 0.893
29054 10121 ACTR1A 0.857
809981 2879 GPX4 0.857
Table 7.2 lists the Image Clone ID, Gene Symbol, Gene ID, and the diseases
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associated with it according to Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) [7] analysis.
Table 7.2: The list of genes with DAVID’s analysis [7]
Image
Clone
ID
Entrez
Gene
Symbol
Entrez
Gene
ID
DAVID’s analysis
36775 HADHA 3030 1) HELLP syndrome, maternal of pregnancy
2) LCHAD deficiency
949938 CST3 1471 1) A genome-wide association for kidney func-
tion and endocrine-related traits in the NHLBI’s
Framingham Heart Study.
2) Cerebral amyloid angiopathy
3) Macular degeneration, age-related, 11
4) New loci associated with kidney function
73531 ISCU 23479 Myopathy with lactic acidosis, hereditary
34357 ACTB 60 Dystonia, juvenile-onset
23019 GNAS 2778 1) Acromegaly
2) Genome-wide association study of theta band
event-related oscillations identifies serotonin re-
ceptor gene HTR7 influencing risk of alcohol de-
pendence.
3) McCune-Albright syndrome
4) Osseous heteroplasia, progressive
5) Pituitary ACTH secreting adenoma, somatic
6) Pituitary ACTH secreting adenoma, somatic
219090
7) Pseudohypoparathyroidism Ia
8) Pseudohypoparathyroidism Ib
9) Pseudohypoparathyroidism Ic
10) Pseudopseudohypoparathyroidism
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Chapter 8
Impact of our work
In this chapter, we have compared the results, achieved from our hybrid method,
with other cancer studies biologically and statistically in order to evaluate the im-
pact of our work. The biological significance of the identified genes is discussed; by
referencing the identified genes in existing studies, through analyzing transcription
factors, and through the biological significance of genes through Protein-Protein
interaction network. The statistical significance of the identified genes is calcu-
lated based on GSEA measurements.
This chapter is organized as follows. Section 8.1 discuss the biological sig-
nificance of the identified genes through referencing the existing studies (8.1.1),
through analyzing Transcription Factors (8.1.2), through Protein-Protein inter-
action network (8.1.3) and through finding common genes between our identified
genes and genes identified by other studies (8.1.4). The statistical significance of
our identified genes is discussed in Section 8.2.1.
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8.1 Biological significance of the selected genes
8.1.1 Biological significance as referenced by the existing studies
HADHA: Interestingly, HADHA expression has been identified having a strong
association with the risk of breast cancer [54]. The DAVID gene expression anal-
ysis tool also reveals that HADHA gene is associated with HELLP syndrome.
HELLP syndrome comprises of a group of symptoms that occur in pregnant
women who have H (hemolysis i.e., breakdown of red blood cells), EL (elevated
liver enzymes) and LP (low platelet count). M¨uller et al. [55] reported a statis-
tically significant difference in methylation of adenomatous polyposis coli (APC)
[56] in the sera of healthy pregnant women and women who later developed severe
HELLP syndrome, perhaps offering a possible tool for early detection of this severe
disease in pregnancy. They also described for the first time in a phenomenlogic
way that methylations changes in the sera of women in early pregnancy are simi-
lar to those in the sera of patients with advanced breast cancer. These evidently
justify selection of this gene (related to HELLP syndrome, that is different in
terms of its expression in between BRCA1 and BRCA2) as it causes advancement
of breast cancer.
TOB1: TOB1 is a protein that in human is encoded by the TOB1 gene.
O’Malley et al. [57] have shown that TOB1 is expressed in the normal breast
epithelial cells (the thin tissue forming the outer layer of a body’s surface and
lining the alimentary canal and other hollow structures) and that the reduction
or loss of TOB1 expression is associated with breast cancer progression. Helms et
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al. [58] showed a significantly shorter distant metastasis-free survival for breast
cancer patients with high TOB1 expression levels.
CST3: Cystatin C or cystatin 3 is a protein encoded by the CST3 gene,
and is mainly used as a biomarker of kidney function. The cystatin superfamily
encompasses proteins that contain multiple cystatin-like sequences. Some of the
members are active cysteine protease inhibitors, while others have lost or perhaps
never acquired this inhibitory activity. Yano et al. [59] reported a significant
reduction in relative cystatin C expression to the cathepsin B expression which was
detected in breast cancer tissue. The study concluded that cystatin C expression
plays a role in cancer invasion and metastasis. In another study Vigneswaran
et al. [60] showed for a limited set of tumor samples that cystatin M and C are
expressed in primary breast cancer with lymph node metastasis. It concluded that
increased expression levels of both cystatin M and C are significantly correlated
with larger tumor size in breast cancer. Similarly Tumminello et al. [61] reported
that cystatin C levels were significantly higher in breast cancer patients than in
controls or patients with osteoporosis.
ACTB: Beta-actin (gene name ACTB) is one of the six different actin iso-
forms which have been identified in human. Ambrosino et al. [62] identified
that the actin network plays a role in nuclear ER-alpha actions in breast cancer
cells, including coordinated regulation of target gene activity, spatial and func-
tional reorganization of chromatin, and ribosome biogenesis. ACTB gene has also
been identified as one of the significant genes to quantify urokinase plasminogen
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activator in breast cancer [63]. It is worth mentioning here that the urokinase plas-
minogen activator is a well known system that causes the progression of malignant
cancer at various steps [64].
ISCU: Iron-sulfur cluster assembly enzyme ISCU, mitochondrial is a protein
that in human is encoded by the ISCU gene. Favaro et al. [65] found a highly
significant inverse relationship of miR-210 to ISCU expression in 216 patients with
breast cancer.
GPX4: Glutathione peroxidase 4, also known as GPX4, is an enzyme that in
human is encoded by the GPX4 gene. Udler et al. [66] reported that the common
variation in GPX4 is associated with the prognosis after a diagnosis of breast
cancer. In another study, Heirman et al. [67] reported that GPX4 overexpression
drastically impeded solid tumor growth in certain cells.
ACTR1A: Alpha-centractin is a protein that in human is encoded by the
ACTR1A gene. The most abundant subunits of dynactin, which is associated with
the transport of p53 to the nucleus, are encoded by ACTR1A. Disruption of this
ACTR1A-dynactin complex via mutations in ACTR1A could potentially result
in p53 inactivation, which is intriguing, given the absence of known inactivating
mutations in p53 in malignant pleural mesothelioma (MPM) tumors [68].
8.1.2 Biological significance through analyzing of transcription factors
Transcription factors are specialized proteins that bind to specific sites on DNA
and turn on or off the expression of different sets of genes. The basic structure
of every transcriptional factor mainly contains a DNA-binding domain and an
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Figure 8.1: Transcription factor network linked with the selected gene set
activator domain [69]. For improvement of disease treatment strategies, recent
studies are concentrating on the identification of different transcription factors
and blocking them. Transcription factors are known to play a key role in regu-
lating pathways, by controlling the levels of pathway gene expression [70]. We
used TRANScription FACtor database’s (TRANSFAC) [71] transcription factors
that were in GMT (Gene Matrix Transposed) format. In order to find those tran-
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scription factors that cover the identified 8 genes and BRCA1 and BRCA2, we
used minimum hitting set algorithm [72] i.e. we selected only those transcription
factors that covered the minimum number of genes including the identified genes.
We found 8 different transcription factors that covered the identified genes and
BRCA1 and BRCA2 as shown in Figure 8.4. One of the transcription factors
that cover the identified genes, ATF6 (activating transcription factor 6 [73]) has
already been linked with cancer [74]. In summary, the transcription factors that
cover the identified 8 genes also control the breast cancer genes i.e. BRCA1 and
BRCA2.
8.1.3 Significance of the genes based on Protein-Protein interaction
network
Figure 8.2 shows the Protein-Protein interaction network for the identified 8 genes,
their other neighboring genes and BRCA1 and BRCA2. For simplicity and visi-
bility we have removed the genes that form small clusters, and have renamed the
cluster with the corresponding gene symbol that is at the center.
After analyzing the Protein-Protein interaction network, we identified 5 genes,
namely ACTB, TOB1, HADHA, GNAS and ACTR1A that form individual clus-
ters and are not directly linked with BRCA2 or BRCA2. Therefore, these genes
need to communicate with BRCA1 or BRCA2 indirectly i.e., through other genes.
It is interesting to note that 6 genes, namely SMARCC2, POLR2A, H2AFX,
SMARCA4, MGMT, SMAD3 and SKP2, provide the communication between
BRCA1 and BRCA2 and the other genes. Hence, these genes serve as a “barrier”
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for BRCA1 and BRCA2 since they can stop any undesirable communication to
BRCA1 and BRCA2.
Figure 8.2 shows that TOB1 is indirectly linked with both BRCA1 and BRCA2
through ESR1, SMAD3 and SKP2. Hence, it is a possibility that TOB1 commu-
nicates with either BRCA1 or BRCA2 or both through these 3 genes. If they can
be suppressed, the communication between TOB1 and BRCA1 and/or TOB1 and
BRCA2 will be broken. Another interesting fact is that TOB1 forms a cluster
with 10 other genes that is mostly dominated by SMAD variants (1, 4, 5 and 9),
with itself at the center. This leads to an assumption that these 10 genes are
very closely correlated with TOB1 and can influence TOB1. Under their influ-
ences TOB1 may overexpress/underexpress while communicating with BRCA1 or
BRCA2 or both through ESR1, SMAD3 or SKP2.
Figure 8.2 also shows that ACTB is indirectly linked with BRCA1 and BRCA2
through SMARCC2. Hence, it is possible that ACTB communicates with BRCA1
or BRCA2 or both through this gene. Hence, this indirect communication can
be broken by silencing/suppressing this mediator gene. In addition, ACTB forms
a cluster of 33 genes that is mostly dominated by CCT variants (6a, 7, 3, 4, 5,
8) with itself at the center. If these genes are silenced, the link between them
and BRCA1 or BRCA2 or both can be broken. Another interesting fact is that
ACTB is directly connected with CST3 and indirectly connected with ACTR1A
cluster through SPTBN2. There is a strong possibility that CST3 or ACTR1A
can influence ACTB or vice versa.
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Figure 8.2: Protein-Protein interaction network reflecting the linkage between the
selected gene set and BRCA1 or BRCA2 or both
Another identified gene ACTR1A forms a cluster with 8 genes that is mostly
dominated by DCTN variant genes (1, 2, 3, 4) with itself and DCTN4 at the center.
ACTR1A does not communicate with any gene that is a neighbor of BRCA1
or BRCA2 or both. However, it communicates with ACTB through SPTBN2.
If ACTR1A is influencing BRCA1 and BRCA2 or both, this can be stopped
by suppressing the SPTBN2 gene. Similarly ACTR1A is directly linked with
KIAA0101 that itself is connected with SMARCC2 and POLR2A. Furthermore,
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KIAA0101 is also connected with HADHA and GNAS. Hence, if HADHA or
GNAS or ACTR1A are being influenced by genes in their respective clusters or
by each other, then the link can be broken by silencing KIAA0101.
GNAS forms a cluster of 11 genes with itself at the center. It is directly linked
with CST3 which can influence it or vice versa. Moreover, GNAS is indirectly
linked with ACTB through CST3. This connection can be broken by silencing
CST3 in case of any overexpression/underexpression of either of the three genes.
GNAS is also connected with HADHA through SHMT2 and both of these genes
can influence each other. This can be stopped by silencing SHMT2. In addition,
GNAS is indirectly connected with KIAA0101 through PAICS. If it is influencing
KIAA0101, then by silencing PAICS this connection can be broken.
HADHA forms a cluster of 14 genes with itself at the center. HADHA is
directly connected with KIAA0101 that itself is connected with GNAS, ACTR1A,
POLR2A and SMARCC2. HADHA might be influenced by GNAS or it can
influence KIAA0101. This can be stopped by silencing KIAA0101.
8.1.4 The genes that have been already identified by other cancer
literature
In order to compare our findings with other cancer literature, we find the common
genes among the identified genes using our approach and those identified by other
cancer literature. Out of the 8 identified genes using our hybrid method, 5 genes
have been mapped with existing literature. Table 8.1 shows a summarized view
of the existing studies and the list of genes that are common between them and
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our identified list.
Table 8.1: A summarized view of existing studies and their common genes with
our identified list
Author(s) Genes Common
Genes
Count
Total
Genes
Reference
Hedenfalk et al. HADHA, TOB1, ISCU,
ACTR1A, GPX4
5 51 [1]
Storey et al. HADHA, ACTR1A, GPX4 3 - [2]
Lee et al. TOB1, ISCU 2 27 [4]
Qizhong TOB1, ISCU 2 20 [5]
Zhou et al. TOB1, GPX4 2 20 [3]
Xiong et al. HADHA, ACTR1A 2 20 [6]
Out of the 8 identified genes by our hybrid method, at least 3 genes (HADHA,
ACTR1A and GPX4) were identified as important by Hedenfalk et al. [1] and
Storey et al. [2]. Moreover, 2 genes (TOB1 and ISCU) were also identified as
important by Hedenfalk et al. [1], Lee et al. [4] and Qizhong [5]. Furthermore,
2 genes ( TOB1 and GPX4) were also listed as important by Hedenfalk et al.
[1] and Zhou et al. [3]. Lastly, 2 genes (HADHA and ACTR1A) were listed
as important by Hedenfalk et al. [1] and Xiong et al. [6]. For the purpose of
clarity and easy understanding, Figure 8.3 shows a stacked diagram of the genes
identified using the hybrid method that were also identified as important by other
studies.
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Figure 8.3: A stack diagram (grouped list) showing the genes that are common
between genes identified by other cancer studies and our identified gene set and
the total genes for each study (common genes/total genes).
8.2 Statistical significance of the selected genes
8.2.1 GSEA measurement
It is interesting to consider the results of gene set enrichment analysis (GSEA) on
our set of 8 genes, identified by the hybrid method, against the other gene sets
proposed by Hedenfalk et al. [1] (51 genes), Lee et al. [4] (27 genes), Qizhong [5]
(20 genes) and 8 other studies. Five out of the 8 identified genes are enriched in
BRCA1, while the remaining 3 are enriched in BRCA2. Moreover, the identified
gene set has an enrichment score of 0.52 (fourth best in the list and better than
Zhou et al. [43], Mamtani et al. [54] and Mao et al. [75]), and members of the
76
Figure 8.4: Gene Set Enrichment Analysis (GSEA) for our genes and other studies
leading edge subset (i.e., tags = 63%, list = 14% and signal = 72%) is fourth
best and better than Hedenfalk et al. [1], Zhou et al. [43], Mamtani et al. [54]
and Mao et al. [75]. Furthermore, out of the 8 identified genes, 2 (ACTR1A and
HADHA) are in the top 50 rank in gene list (ACTR1A is at third and ISCU is
at seventeenth position) computed by GSEA with an enrichment score of ≥ 0.95.
The most important point to note here is that the 8 genes identified by the hybrid
method is the ‘smallest’ size of gene set in the GSEA analysis. These comparisons
indicate that identified gene set contains mostly those genes contributing to the
enrichment score, compared to the other gene sets that contain only a fraction of
genes contributing to the enrichment score.
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Chapter 9
Conclusion
We have proposed a hybrid feature selection method in this paper and used it
to identify important genes that are biological significant using their expression
levels. We have used the area under the ROC curve (AUC) measure and hidden
Markov model (HMM) to obtain a small subset of important genes. Here we have
set AUC threshold to ≥ 0.8 to filter all less important genes. The filtered gene list
is then forwarded to the HMM that has 103 states. After the HMM is modeled,
we analyze the observation emission and state transition probabilities to iden-
tify the important gene subset. In order to evaluate the impact of our work, we
have compared our results with other cancer studies biologically and statistically.
The biological significance of the identified genes is discussed; by referencing the
identified genes in existing studies, through analyzing transcription factors, and
through the biological significance of genes through Protein-Protein interaction
network. The statistical significance of the identified genes is calculated based on
GSEA measurements. The results of these comparisons confirm that our method
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identified the high impact and biologically relevant genes that contribute towards
discriminating BRCA1 mutation from BRCA2 mutation in hereditary breast can-
cer.
9.1 Significance of our work
We believe our work can help biologists and researchers in the following ways:
• Biologists can perform an in-depth study of identified genes in order to come
up with new medicine that can either cure the disease or at the very least
restrict the growth of the disease, resulting in an extended life of the patient,
in case the cure is not possible.
• Identification of important genes and their rigorous study can result in new
methods of detection of the disease so that early prognosis can be done and
the affected patient can be informed at the earliest, or the disease can be
predicted before it actually affects the patient.
• Researchers can use the algorithm to find important genes in a dataset
– Without the use of laboratories and expensive equipment,
– Without waiting for lab results
9.2 Limitations
Although the research has reached its aims, there were some unavoidable limita-
tions. First, the sample size in the dataset was extremely small i.e., 22 patients
out of which only 15 were related to over problem. Secondly, although we used
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Leave one out cross-validation (LOOCV) to maximize the available samples in
the dataset and avoid any overfitting, still the sample size was extremely small.
Hence, the proposed method may suffer from overfitting. Thirdly, the proposed
method may be successtible to noise. Fourthly, the comparison done with other
techniques might not be very relevant since those techniques identified genes in-
dividually whereas our method is identifying genes collectively. Finally, since we
do not have access to a wet laboratory, we are unable to genetically justify the
selection of the identified genes.
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